Stephen S. Myatt

3.3k total citations · 1 hit paper
18 papers, 2.7k citations indexed

About

Stephen S. Myatt is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Stephen S. Myatt has authored 18 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 7 papers in Oncology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Stephen S. Myatt's work include FOXO transcription factor regulation (10 papers), Cancer Mechanisms and Therapy (4 papers) and Retinoids in leukemia and cellular processes (4 papers). Stephen S. Myatt is often cited by papers focused on FOXO transcription factor regulation (10 papers), Cancer Mechanisms and Therapy (4 papers) and Retinoids in leukemia and cellular processes (4 papers). Stephen S. Myatt collaborates with scholars based in United Kingdom, Taiwan and Hong Kong. Stephen S. Myatt's co-authors include Eric W.‐F. Lam, R. Charles Coombes, Jimmy M-M. Kwok, Jan J. Brosens, Barrie Peck, Ka-Kei Ho, Lara J. Monteiro, Demetra Constantinidou, Chwan‐Deng Hsiao and Chun‐Yuan Chen and has published in prestigious journals such as Nature reviews. Cancer, Cancer Research and Oncogene.

In The Last Decade

Stephen S. Myatt

18 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The emerging roles of forkhead box (Fox) proteins in cancer

2007 879 citations Stephen S. Myatt, Eric W.‐F. Lam Nature reviews. Cancer profile →

Peers

Countries citing papers authored by Stephen S. Myatt

Since Specialization

Citations

This map shows the geographic impact of Stephen S. Myatt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen S. Myatt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen S. Myatt more than expected).

Fields of papers citing papers by Stephen S. Myatt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen S. Myatt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen S. Myatt. The network helps show where Stephen S. Myatt may publish in the future.

Co-authorship network of co-authors of Stephen S. Myatt

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen S. Myatt. A scholar is included among the top collaborators of Stephen S. Myatt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen S. Myatt. Stephen S. Myatt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Abstract LB040: MACO-355, a unique pan-LILR monoclonal antibody for cancer therapy, re-programs and stimulates immuno-suppressive macrophages in a novel ligand-binding blocking independent manner 2024 ·Cancer Research ·Krzysztof B. Wicher, Moritz Haneklaus, Martha Lopez‐Yrigoyen, (unknown), (unknown), Maikel Fransen, (unknown), (unknown), Luca Cassetta, Stephen S. Myatt, Carola H. Ries	1
2	SUMOylation inhibits FOXM1 activity and delays mitotic transition 2013 ·Oncogene ·Stephen S. Myatt, Mesayamas Kongsema, (unknown), Douglas J. Kelly, Ana Gomes, Pasarat Khongkow, (unknown), Stefania Zona, Julia Langer, Christopher Dunsby, R. Charles Coombes, P. M. W. French, Jan J. Brosens, Eric W.‐F. Lam	85
3	SIRT Inhibitors Induce Cell Death and p53 Acetylation through Targeting Both SIRT1 and SIRT2 2010 ·Molecular Cancer Therapeutics ·Barrie Peck, Chun‐Yuan Chen, Ka-Kei Ho, Paolo Di Fruscia, Stephen S. Myatt, R. Charles Coombes, Matthew J. Fuchter, Chwan‐Deng Hsiao, Eric W.‐F. Lam	371
4	FOXM1 Confers Acquired Cisplatin Resistance in Breast Cancer Cells 2010 ·Molecular Cancer Research ·Jimmy M-M. Kwok, Barrie Peck, Lara J. Monteiro, Helma D.C. Schwenen, Julie Millour, R. Charles Coombes, Stephen S. Myatt, Eric W.‐F. Lam	167
5	Sense and Sensitivity: FOXO and ROS in Cancer Development and Treatment 2010 ·Antioxidants and Redox Signaling ·Stephen S. Myatt, Jan J. Brosens, Eric W.‐F. Lam	62
6	FOXM1 is a transcriptional target of ERα and has a critical role in breast cancer endocrine sensitivity and resistance 2010 ·Oncogene ·Julie Millour, Demetra Constantinidou, Alexandra Stavropoulou, Miranda Wilson, Stephen S. Myatt, Jimmy M-M. Kwok, Kavitta Sivanandan, R. Charles Coombes, René H. Medema, Johan Hartman, Anne E. Lykkesfeldt, Eric W.‐F. Lam	132
7	Definition of microRNAs That Repress Expression of the Tumor Suppressor Gene FOXO1 in Endometrial Cancer 2009 ·Cancer Research ·Stephen S. Myatt, Jun Wang, Lara J. Monteiro, Mark Christian, Ka-Kei Ho, Luca Fusi, Roberto Dina, Jan J. Brosens, Sadaf Ghaem‐Maghami, Eric W.‐F. Lam	284
8	Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer 2009 ·Molecular Cancer Therapeutics ·Ursula McGovern, Richard E. Francis, Barrie Peck, Stephanie K. Guest, Jun Wang, Stephen S. Myatt, (unknown), Jimmy M-M. Kwok, Andreas Polychronis, R. Charles Coombes, Eric W.‐F. Lam	115
9	The novel molecule 2‐[5‐(2‐chloroethyl)‐2‐acetoxy‐benzyl]‐4‐(2‐chloroethyl)‐phenyl acetate inhibits phosphoinositide 3‐kinase/Akt/mammalian target of rapamycin signalling through JNK activation in cancer cells 2009 ·FEBS Journal ·(unknown), (unknown), (unknown), Mark E. B. Smith, Alexandra Stavropoulou, Erika Rosivatz, (unknown), John B. Wong, Valerie Lafitte, (unknown), Stephen S. Myatt, (unknown), Rüdiger Woscholski, Eric W.‐F. Lam	6
10	Targeting FOXM1 2008 ·Nature reviews. Cancer ·Stephen S. Myatt, Eric W.‐F. Lam	47
11	Many forks in the path: cycling with FoxO 2008 ·Oncogene ·(unknown), Stephen S. Myatt, Eric W.‐F. Lam	143
12	Manipulation of oxidative stress to induce cell death in Ewing’s sarcoma family of tumours 2008 ·European Journal of Cancer ·Tapiwanashe Magwere, Stephen S. Myatt, Susan A. Burchill	19
13	Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression 2008 ·Molecular Cancer Therapeutics ·Jimmy M-M. Kwok, Stephen S. Myatt, Charles M. Marson, R. Charles Coombes, Demetra Constantinidou, Eric W.‐F. Lam	206
14	Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells 2008 ·Molecular Cancer Therapeutics ·(unknown), Richard E. Francis, Stephanie K. Guest, Joana R. Costa, Ana Gomes, Stephen S. Myatt, Jan J. Brosens, Eric W.‐F. Lam	165
15	The sensitivity of the Ewing's sarcoma family of tumours to fenretinide-induced cell death is increased by EWS-Fli1-dependent modulation of p38MAPK activity 2007 ·Oncogene ·Stephen S. Myatt, Susan A. Burchill	18
16	The emerging roles of forkhead box (Fox) proteins in cancer breakdown → 2007 ·Nature reviews. Cancer ·Stephen S. Myatt, Eric W.‐F. Lam	879
17	Promiscuous and lineage-specific roles of cell cycle regulators in haematopoiesis. 2007 ·Cell Division ·Stephen S. Myatt, Eric W.‐F. Lam	7
18	p38MAPK-Dependent Sensitivity of Ewing's Sarcoma Family of Tumors to Fenretinide-Induced Cell Death 2005 ·Clinical Cancer Research ·Stephen S. Myatt, Christopher P.F. Redfern, Susan A. Burchill	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact